CA2996415A1 - Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders - Google Patents

Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Download PDF

Info

Publication number
CA2996415A1
CA2996415A1 CA2996415A CA2996415A CA2996415A1 CA 2996415 A1 CA2996415 A1 CA 2996415A1 CA 2996415 A CA2996415 A CA 2996415A CA 2996415 A CA2996415 A CA 2996415A CA 2996415 A1 CA2996415 A1 CA 2996415A1
Authority
CA
Canada
Prior art keywords
moiety
compound
bond
pharmaceutically acceptable
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2996415A
Other languages
English (en)
French (fr)
Inventor
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao GADHACHANDA
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of CA2996415A1 publication Critical patent/CA2996415A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
CA2996415A 2015-08-26 2016-08-25 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Pending CA2996415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209972P 2015-08-26 2015-08-26
US62/209,972 2015-08-26
PCT/US2016/048696 WO2017035353A1 (en) 2015-08-26 2016-08-25 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Publications (1)

Publication Number Publication Date
CA2996415A1 true CA2996415A1 (en) 2017-03-02

Family

ID=58100965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2996415A Pending CA2996415A1 (en) 2015-08-26 2016-08-25 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Country Status (22)

Country Link
US (5) US10011612B2 (enExample)
EP (2) EP4053117A1 (enExample)
JP (3) JP6877406B2 (enExample)
KR (1) KR102668548B1 (enExample)
CN (2) CN108024992A (enExample)
AR (1) AR106018A1 (enExample)
AU (2) AU2016311425B2 (enExample)
CA (1) CA2996415A1 (enExample)
DK (1) DK3340981T3 (enExample)
EA (2) EA201992884A3 (enExample)
ES (1) ES2935633T3 (enExample)
FI (1) FI3340981T3 (enExample)
HU (1) HUE061088T2 (enExample)
IL (2) IL257175B (enExample)
MX (2) MX2018002399A (enExample)
PL (1) PL3340981T3 (enExample)
PT (1) PT3340981T (enExample)
RU (1) RU2743298C2 (enExample)
SI (1) SI3340981T1 (enExample)
TW (1) TW201722932A (enExample)
WO (1) WO2017035353A1 (enExample)
ZA (1) ZA201800641B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3110805B1 (en) 2014-02-25 2019-12-11 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035361A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
CA3007922A1 (en) * 2015-12-11 2017-06-15 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018229543A2 (en) * 2017-06-14 2018-12-20 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3661493A4 (en) * 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
JP7566731B2 (ja) 2018-07-03 2024-10-15 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7538113B2 (ja) * 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
CA3114039A1 (en) * 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
MA54753A (fr) * 2019-01-17 2021-11-24 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
WO2021067801A1 (en) * 2019-10-03 2021-04-08 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN115362162A (zh) * 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021183555A1 (en) * 2020-03-10 2021-09-16 Achillion Pharmaceuticals, Inc. Ocular drug depot for complement-mediated disorders
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
WO2022047128A2 (en) * 2020-08-28 2022-03-03 Alexion Pharmaceuticals, Inc. Method for treating complement mediated disorders caused by betacoronaviruses
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
US12152018B2 (en) 2021-01-08 2024-11-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with STING activity
UA124724C2 (uk) * 2021-03-26 2021-11-03 Consortium Ukrindustry Спосіб отримання ліпосомальної композиції, що містить латанопрост, та фармакологічно активна ліпосомальна композиція для офтальмотерапії, отримана таким способом
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
EP4419097A1 (en) * 2021-10-18 2024-08-28 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy
CN114437043B (zh) * 2022-02-02 2023-06-16 浙江乐普药业股份有限公司 一种抗新冠药物Nirmatrelvir的制备方法
WO2024008121A1 (zh) * 2022-07-06 2024-01-11 南京明德新药研发有限公司 二氟取代的氮杂双环化合物及其应用
WO2024102986A2 (en) * 2022-11-10 2024-05-16 The Texas A&M University System Sars-cov-2 mpro inhibitors
WO2024259085A2 (en) * 2023-06-14 2024-12-19 Alexion Pharmaceuticals, Inc. Methods for the synthesis of complement factor d inhibitors and intermediates thereof

Family Cites Families (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013557A (en) 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
PT797987E (pt) 1994-12-19 2004-02-27 Daiichi Seiyaku Co Preparacao granular de libertacao controlada e processo para a sua preparacao
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
DE69628276T2 (de) 1995-07-26 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Zubereitung von xanthinderivaten als feste dispersion
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
PT910412E (pt) 1996-07-01 2003-09-30 Univ Utrecht Hidrogeis hidrolisaveis para libertacao controlada
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
WO1998055471A1 (en) 1997-06-03 1998-12-10 Biocryst Pharmaceuticals, Inc. Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
EP1072263A4 (en) * 1998-03-26 2004-03-31 Japan Tobacco Inc AMID DERIVATIVES AND NOCICEPTINANT AGONISTS
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
WO2001017980A1 (en) 1999-09-03 2001-03-15 Ajinomoto Co., Inc. Novel processes for preparing oxazepine derivatives
GB9927011D0 (en) 1999-11-16 2000-01-12 Advanced Phytonics Ltd Method for the production of particles
ATE297196T1 (de) 1999-12-20 2005-06-15 Nicholas J Kerkhof Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
OA12124A (en) 1999-12-23 2006-05-05 Pfizer Prod Inc Pharmmaceutical compositions providing enhanced drug concentrations.
EP1967185A1 (en) 1999-12-23 2008-09-10 Pfizer Products Inc. Hydrogel-driven drug dosage form
MXPA02008361A (es) 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
US7455855B2 (en) 2000-04-03 2008-11-25 Santen Pharmaceutical Co., Ltd. Delivering substance and drug delivery system using the same
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ATE378039T1 (de) 2000-06-27 2007-11-15 Vectura Ltd Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
GB0021024D0 (en) 2000-08-29 2000-10-11 Glaxo Group Ltd Inhalation device
WO2002036169A2 (en) 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
PT1337239E (pt) 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
MXPA04007428A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20060100431A1 (en) 2002-07-16 2006-05-11 Amura Therapeutics Limited Biologically active compounds
EP2311479B1 (en) 2002-09-20 2014-07-23 The Trustees of The University of Pennsylvania Compstatin analogs with improved activity
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7431026B2 (en) * 2003-04-22 2008-10-07 Avalon Advanced Products, Inc Paintball refillers and method for making and using same
AU2003902946A0 (en) 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
EP1663180A1 (en) 2003-09-15 2006-06-07 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
EP1694731B1 (en) 2003-09-23 2012-03-28 University Of North Carolina At Chapel Hill Photocurable perfluoropolyethers for use as novel materials in microfluidic devices
SE0302665D0 (sv) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
PT1704585T (pt) 2003-12-19 2017-05-05 Univ North Carolina Chapel Hill Métodos para fabricar microestruturas e nanoestruturas isoladas usando litografia suave ou impressão litográfica
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US8158728B2 (en) 2004-02-13 2012-04-17 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
PL1727811T3 (pl) 2004-03-24 2015-04-30 Shire Orphan Therapies Gmbh Nowe związki do hamowania angiogenezy i ich zastosowanie
GB0407627D0 (en) 2004-04-02 2004-05-05 Vectura Ltd Corkscrew pump
SI1755616T1 (sl) 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
PL370285A1 (pl) 2004-09-23 2006-04-03 Glaxosmithkline Pharmaceuticals Spółka Akcyjna Inhalator proszkowy
WO2006079921A2 (en) 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
US20060182771A1 (en) 2005-02-09 2006-08-17 Dor Philippe J Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2611985C (en) 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20070178133A1 (en) 2005-11-09 2007-08-02 Liquidia Technologies, Inc. Medical device, materials, and methods
CN101400692B (zh) 2005-11-28 2013-01-02 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
WO2007070556A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
EP1962803A1 (en) 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
JP5819579B2 (ja) 2006-01-13 2015-11-24 サーモディクス，インコーポレイティド 薬物送達のためのマトリックスを含む微粒子
KR20080110800A (ko) 2006-03-15 2008-12-19 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US20100003291A1 (en) 2006-05-15 2010-01-07 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
UA101468C2 (ru) * 2006-07-13 2013-04-10 Ачілліон Фармасьютікалз, Інк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
GB0617480D0 (en) 2006-09-06 2006-10-18 Univ Sheffield Novel nanoparticles
JP2010502713A (ja) 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
EP2108642A1 (en) 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
US8632809B2 (en) 2006-11-09 2014-01-21 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
WO2008100304A2 (en) 2006-11-15 2008-08-21 The University Of North Carolina At Chapel Hill Polymer particle composite having high fidelity order, size, and shape particles
KR20090109551A (ko) 2007-01-15 2009-10-20 산텐 세이야꾸 가부시키가이샤 ＩκＢ 키나아제 β 저해 활성을 갖는 신규 인돌 유도체
WO2008097525A2 (en) 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
AU2008334637B2 (en) 2007-12-11 2014-08-07 Glaxo Group Limited Antigen binding proteins
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2276420B1 (en) 2008-04-04 2021-10-06 Journey1, Inc. Device to treat an eye having an epithelium with a defect
CN102112118A (zh) 2008-04-25 2011-06-29 北卡罗来纳-查佩尔山大学 特别用于非湿润模型的颗粒复制的可降解化合物及其使用方法
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
WO2010009087A1 (en) 2008-07-15 2010-01-21 Eyegate Pharmaceuticals, Inc. Iontophoretic delivery of a controlled-release formulation in the eye
NZ600622A (en) 2008-08-05 2013-12-20 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
ES2579902T3 (es) 2008-10-08 2016-08-17 Astrazeneca Ab Dispositivo de inhalación para administrar un medicamento
MX340857B (es) 2008-12-05 2016-07-28 Liquidia Tech Inc Metodo para producir materiales modelados.
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US20120052041A1 (en) 2009-02-04 2012-03-01 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
WO2010093662A2 (en) 2009-02-10 2010-08-19 Psivida Us, Inc. Ocular trocar assembly
ES2655714T3 (es) 2009-02-26 2018-02-21 The University Of North Carolina At Chapel Hill Sistema intervencionista de administración de fármacos
CN102458438A (zh) 2009-05-01 2012-05-16 宾夕法尼亚州大学理事会 具有肽骨架和c-末端修饰的经修饰补体抑素
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CN104887388B (zh) 2009-06-03 2018-01-09 弗赛特影像5股份有限公司 前段药物输送
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
WO2011046204A1 (ja) 2009-10-16 2011-04-21 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
WO2011050365A1 (en) 2009-10-23 2011-04-28 Forsight Labs, Llc Conformable therapeutic shield for vision and pain
NO2490635T3 (enExample) 2009-10-23 2018-02-03
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
TWI478730B (zh) 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
BR112012016129B1 (pt) 2009-12-31 2020-11-03 Hutchison Medipharma Limited composto, composição e uso dos ditos compostos
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
MY173699A (en) 2010-04-16 2020-02-17 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
NZ603345A (en) 2010-05-05 2014-12-24 Alcon Res Ltd Stabilized ophthalmic galactomannan formulations
WO2011153349A1 (en) 2010-06-02 2011-12-08 Alcon Research, Ltd. Ophthalmic compositions comprising pbo-peo-pbo block copolymers
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012006599A2 (en) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
US20130274692A1 (en) 2010-08-05 2013-10-17 Yair Alster Subconjuctival implant for posterior segment drug delivery
HRP20211909T1 (hr) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US20140033800A1 (en) 2010-11-11 2014-02-06 Forsight Vision4, Inc. Methods and apparatus to determine diffusion properties of porous structures for drug delivery
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
PE20140471A1 (es) * 2011-01-04 2014-04-13 Novartis Ag Moduladores de la via del complemento y usos de los mismos
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
WO2012145801A1 (en) 2011-04-29 2012-11-01 Jagat Rakesh Kanwar Nanoparticle
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
MX356528B (es) 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
PH12013502455A1 (en) * 2011-05-27 2014-01-20 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
CA2877474A1 (en) 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
ES3044832T3 (en) 2011-06-22 2025-11-27 Apellis Pharmaceuticals Inc Methods of treating chronic disorders with complement inhibitors
US20130035392A1 (en) 2011-08-01 2013-02-07 Mcgeer Patrick L Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
WO2013036778A2 (en) 2011-09-07 2013-03-14 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
EP4643921A2 (en) 2011-09-16 2025-11-05 ForSight Vision4, Inc. Fluid exchange apparatus
EP2785326A2 (en) 2011-11-29 2014-10-08 The University of North Carolina at Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
CA2859046C (en) 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
PT2797652T (pt) 2011-12-27 2019-02-19 Vectura Gmbh Dispositivo para inalação com sistema de feedback
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6174056B2 (ja) 2012-03-09 2017-08-02 ベクチュラ・ゲーエムベーハー 吸入用装置及び吸入用装置のための混合流路
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
NZ742005A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339B1 (en) 2012-05-03 2025-11-12 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
ES2630079T3 (es) 2012-05-04 2017-08-17 Novartis Ag Moduladores de la ruta del complemento y usos de los mismos
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
ES2864857T3 (es) * 2012-06-18 2021-10-14 Omeros Corp Composiciones y métodos para la inhibición de MASP-1 y/o MASP-2 y/o MASP-3 para el tratamiento de diversas enfermedades y trastornos
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104640855B (zh) 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
EA201590118A1 (ru) * 2012-06-28 2015-04-30 Новартис Аг Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
ES2647124T3 (es) * 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
ES2710491T3 (es) 2012-06-28 2019-04-25 Novartis Ag Moduladores de la vía del complemento y sus usos
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
AU2013288319A1 (en) 2012-07-12 2015-02-05 Novartis Ag Complement pathway modulators and uses thereof
ES1077714Y (es) 2012-07-31 2012-12-20 Gutierrez Jose Ramon Perez Envase de madera
KR20150054795A (ko) 2012-09-10 2015-05-20 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘
CN104822370A (zh) 2012-09-17 2015-08-05 佰恩德治疗股份有限公司 包含治疗剂的治疗性纳米颗粒及其制备和使用方法
AU2013317899A1 (en) 2012-09-20 2015-05-07 Akina, Inc. Biodegradable microcapsules containing filling material
PL2724741T3 (pl) 2012-10-26 2017-11-30 Vectura Gmbh Urządzenie inhalacyjne do stosowania w terapii aerozolowej
SI2911623T1 (sl) 2012-10-26 2019-12-31 Forsight Vision5, Inc. Oftalmični sistem za podaljšano sproščanje zdravila v oko
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
US9773428B2 (en) 2012-12-11 2017-09-26 Fluidity Software, Inc. Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
CA2899034A1 (en) 2013-01-23 2014-07-31 Musc Foundation For Research Development Targeting constructs based on natural antibodies and uses thereof
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
JP6570513B2 (ja) 2013-04-01 2019-09-04 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP2016169161A (ja) 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
ES2650917T3 (es) 2013-08-07 2018-01-23 Alexion Pharmaceuticals, Inc. Proteínas biomarcadoras del síndrome urémico hemolítico atípico (SUHA)
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
CN105813578A (zh) 2013-10-15 2016-07-27 弗赛特影像5股份有限公司 用于增加或减少粘液的制剂和方法
WO2015066241A1 (en) 2013-10-30 2015-05-07 Novartis Ag 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
MX2016007345A (es) 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.
EP3110805B1 (en) 2014-02-25 2019-12-11 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
WO2017035352A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035417A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
CA3007922A1 (en) 2015-12-11 2017-06-15 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2017123716A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
TWI854164B (zh) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA
JP2020536097A (ja) 2017-10-04 2020-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
CA3114039A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
KR20210104071A (ko) 2018-12-17 2021-08-24 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 표적 투약
JP2022543760A (ja) 2019-07-31 2022-10-14 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤用の投与レジメン
CN112280762B (zh) * 2020-11-13 2022-11-01 中山俊凯生物技术开发有限公司 一种烟酰胺核糖激酶突变体及其编码基因和应用
CN113832125B (zh) * 2021-10-19 2023-09-26 中山百灵生物技术股份有限公司 一种烟酰胺核糖激酶突变体及其编码基因和应用
CN114107160B (zh) * 2021-12-27 2025-04-25 浙江英沃迪生物科技有限公司 一种烟酰胺核糖激酶基因工程菌及其应用
CN114606213B (zh) * 2022-01-28 2024-05-03 浙江工业大学 一种多聚磷酸激酶突变体、工程菌及其应用

Also Published As

Publication number Publication date
US20180305375A1 (en) 2018-10-25
HK1257734A1 (en) 2019-10-25
EP3340981A1 (en) 2018-07-04
PT3340981T (pt) 2023-01-17
CN108024992A (zh) 2018-05-11
DK3340981T3 (da) 2023-01-09
EA201992884A2 (ru) 2020-04-30
IL257175B (en) 2022-09-01
JP2023052297A (ja) 2023-04-11
EA201890594A1 (ru) 2018-08-31
KR102668548B1 (ko) 2024-05-22
IL295844B1 (en) 2024-10-01
MX2018002399A (es) 2018-04-11
AU2016311425B2 (en) 2021-02-04
IL295844B2 (en) 2025-02-01
US12139497B2 (en) 2024-11-12
AU2016311425A1 (en) 2018-02-08
JP7532561B2 (ja) 2024-08-13
JP2018526367A (ja) 2018-09-13
EP4053117A1 (en) 2022-09-07
EA034781B1 (ru) 2020-03-19
US10287301B2 (en) 2019-05-14
CN114044800A (zh) 2022-02-15
EA201992884A3 (ru) 2020-08-31
EP3340981A4 (en) 2019-01-16
WO2017035353A1 (en) 2017-03-02
AR106018A1 (es) 2017-12-06
ZA201800641B (en) 2019-04-24
EP3340981B1 (en) 2022-10-12
MX2022011029A (es) 2022-10-07
JP6877406B2 (ja) 2021-05-26
US20230287005A1 (en) 2023-09-14
US20190211033A1 (en) 2019-07-11
IL295844A (en) 2022-10-01
PL3340981T3 (pl) 2023-03-13
HUE061088T2 (hu) 2023-05-28
KR20180043343A (ko) 2018-04-27
AU2021202728A1 (en) 2021-05-27
IL257175A (en) 2018-03-29
SI3340981T1 (sl) 2023-04-28
JP7210637B2 (ja) 2023-01-23
RU2018110647A (ru) 2019-09-26
RU2018110647A3 (enExample) 2019-12-19
US10822352B2 (en) 2020-11-03
ES2935633T3 (es) 2023-03-08
JP2021119169A (ja) 2021-08-12
RU2743298C2 (ru) 2021-02-16
FI3340981T3 (fi) 2023-01-13
US10011612B2 (en) 2018-07-03
WO2017035353A8 (en) 2018-02-01
TW201722932A (zh) 2017-07-01
AU2021202728B2 (en) 2023-06-08
US20170066783A1 (en) 2017-03-09
US20210269458A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US11649229B2 (en) Amide compounds for treatment of immune and inflammatory disorders
EP3985002B1 (en) Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US10660876B2 (en) Amino compounds for treatment of medical disorders
US11001600B2 (en) Disubstituted compounds for treatment of medical disorders
CA2996415A1 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US10138225B2 (en) Amide compounds for treatment of medical disorders
US10092584B2 (en) Compounds for the treatment of medical disorders
US10000516B2 (en) Phosphonate compounds for treatment of medical disorders
US10385097B2 (en) Ether compounds for treatment of medical disorders
WO2017035415A1 (en) Alkyne compounds for treatment of immune and inflammatory disorders
WO2017035352A1 (en) Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035405A1 (en) Amino compounds for treatment of immune and inflammatory disorders
WO2017035348A1 (en) Alkyne compounds for treatment of medical disorders
EP3589287A1 (en) Macrocyclic compounds for treatment of medical disorders
AU2017290593A1 (en) Quinazoline and indole compounds to treat medical disorders
WO2018160891A1 (en) Pharmaceutical compounds for treatment of medical disorders
WO2017035418A1 (en) Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035413A2 (en) Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035411A1 (en) Ether compounds for treatment of immune and inflammatory disorders
WO2017035417A1 (en) Phosphonate compounds for treatment of immune and inflammatory disorders
EP3340983A1 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AU2020245434A1 (en) Pharmaceutical compounds for the treatment of complement mediated disorders
WO2021168320A1 (en) Heteroaryl compounds for treatment of complement factor d mediated disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810

EEER Examination request

Effective date: 20210810